Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Current Leases (2021 - 2026)

Nurix Therapeutics (NRIX) has disclosed Current Leases for 6 consecutive years, with $3.2 million as the latest value for Q1 2026.

  • Quarterly Current Leases fell 51.77% to $3.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.2 million through Feb 2026, down 51.77% year-over-year, with the annual reading at $2.8 million for FY2025, 64.76% down from the prior year.
  • Current Leases for Q1 2026 was $3.2 million at Nurix Therapeutics, up from $2.8 million in the prior quarter.
  • The five-year high for Current Leases was $8.0 million in Q4 2024, with the low at $2.8 million in Q4 2025.
  • Average Current Leases over 5 years is $5.7 million, with a median of $5.5 million recorded in 2022.
  • The sharpest move saw Current Leases surged 43.75% in 2022, then crashed 64.76% in 2025.
  • Over 5 years, Current Leases stood at $5.5 million in 2022, then skyrocketed by 35.42% to $7.5 million in 2023, then grew by 7.01% to $8.0 million in 2024, then plummeted by 64.76% to $2.8 million in 2025, then rose by 13.39% to $3.2 million in 2026.
  • According to Business Quant data, Current Leases over the past three periods came in at $3.2 million, $2.8 million, and $3.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.